92 related articles for article (PubMed ID: 26239718)
21. Critical assessment of prebiopsy parameters for predicting prostate cancer metastasis and mortality.
van Leeuwen PJ; van den Bergh RC; Wolters T; Zhu X; Bul M; Schröder FH; Bangma CH; Roobol MJ
Can J Urol; 2011 Dec; 18(6):6018-24. PubMed ID: 22166329
[TBL] [Abstract][Full Text] [Related]
22. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence.
Hayes JH; Barry MJ
JAMA; 2014 Mar; 311(11):1143-9. PubMed ID: 24643604
[TBL] [Abstract][Full Text] [Related]
23. Prostate cancer screening using risk stratification based on a multi-state model of genetic variants.
Yen AM; Auvinen A; Schleutker J; Wu YY; Fann JC; Tammela T; Chen SL; Chiu SY; Chen HH
Prostate; 2015 Jun; 75(8):825-35. PubMed ID: 25683204
[TBL] [Abstract][Full Text] [Related]
24. Cancer surveillance using registry data: Results and recommendations for the Lithuanian national prostate cancer early detection programme.
Gondos A; Krilaviciute A; Smailyte G; Ulys A; Brenner H
Eur J Cancer; 2015 Aug; 51(12):1630-7. PubMed ID: 26044924
[TBL] [Abstract][Full Text] [Related]
25. Screening for prostate cancer.
Postma R; Schröder FH
Eur J Cancer; 2005 Apr; 41(6):825-33. PubMed ID: 15808952
[TBL] [Abstract][Full Text] [Related]
26. Metformin for Reducing Racial/Ethnic Difference in Prostate Cancer Incidence for Men with Type II Diabetes.
Wang CP; Lehman DM; Lam YF; Kuhn JG; Mahalingam D; Weitman S; Lorenzo C; Downs JR; Stuart EA; Hernandez J; Thompson IM; Ramirez AG
Cancer Prev Res (Phila); 2016 Oct; 9(10):779-787. PubMed ID: 27026681
[TBL] [Abstract][Full Text] [Related]
27. PSA testing for men at average risk of prostate cancer.
Armstrong BK; Barry MJ; Frydenberg M; Gardiner RA; Haines I; Carter SM
Public Health Res Pract; 2017 Jul; 27(3):. PubMed ID: 28765854
[TBL] [Abstract][Full Text] [Related]
28. Prevention of Prostate Cancer Morbidity and Mortality: Primary Prevention and Early Detection.
Barry MJ; Simmons LH
Med Clin North Am; 2017 Jul; 101(4):787-806. PubMed ID: 28577627
[TBL] [Abstract][Full Text] [Related]
29. Metformin and the risk of prostate cancer across racial/ethnic groups: a population-based cohort study.
Chen CB; Eurich DT; Majumdar SR; Johnson JA
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):122-126. PubMed ID: 28071672
[TBL] [Abstract][Full Text] [Related]
30. Screening for prostate cancer: the current evidence and guidelines controversy.
Gomella LG; Liu XS; Trabulsi EJ; Kelly WK; Myers R; Showalter T; Dicker A; Wender R
Can J Urol; 2011 Oct; 18(5):5875-83. PubMed ID: 22018148
[TBL] [Abstract][Full Text] [Related]
31. American Cancer Society guideline for the early detection of prostate cancer: update 2010.
Wolf AM; Wender RC; Etzioni RB; Thompson IM; D'Amico AV; Volk RJ; Brooks DD; Dash C; Guessous I; Andrews K; DeSantis C; Smith RA;
CA Cancer J Clin; 2010; 60(2):70-98. PubMed ID: 20200110
[TBL] [Abstract][Full Text] [Related]
32. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
[TBL] [Abstract][Full Text] [Related]
33. Prostate cancer screening in Tyrol, Austria: experience and results.
Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
Eur Urol; 1999; 35(5-6):523-38. PubMed ID: 10325519
[TBL] [Abstract][Full Text] [Related]
34. High accuracy of Swedish death certificates in men participating in screening for prostate cancer: a comparative study of official death certificates with a cause of death committee using a standardized algorithm.
Godtman R; Holmberg E; Stranne J; Hugosson J
Scand J Urol Nephrol; 2011 Sep; 45(4):226-32. PubMed ID: 21463227
[TBL] [Abstract][Full Text] [Related]
35. Prospects for automated diagnosis of verbal autopsies.
Garenne M
BMC Med; 2014 Feb; 12():18. PubMed ID: 24495788
[TBL] [Abstract][Full Text] [Related]
36. Variation of Prostate-specific Antigen Value in Men and Risk of High-grade Prostate Cancer: Analysis of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Study.
Boniol M; Autier P; Perrin P; Boyle P
Urology; 2015 May; 85(5):1117-1122. PubMed ID: 25917734
[TBL] [Abstract][Full Text] [Related]
37. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
[TBL] [Abstract][Full Text] [Related]
38. Prostate cancer screening.
Ragsdale JW; Halstater B; Martinez-Bianchi V
Prim Care; 2014 Jun; 41(2):355-70. PubMed ID: 24830612
[TBL] [Abstract][Full Text] [Related]
39. National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making.
Drazer MW; Prasad SM; Huo D; Schonberg MA; Dale W; Szmulewitz RZ; Eggener SE
Cancer; 2014 May; 120(10):1491-8. PubMed ID: 24523016
[TBL] [Abstract][Full Text] [Related]
40. Racial differences in prostate-specific antigen-based prostate cancer screening: State-by-state and region-by-region analyses.
Jindal T; Kachroo N; Sammon J; Dalela D; Sood A; Vetterlein MW; Karabon P; Jeong W; Menon M; Trinh QD; Abdollah F
Urol Oncol; 2017 Jul; 35(7):460.e9-460.e20. PubMed ID: 28256311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
